Status:
TERMINATED
Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy
Lead Sponsor:
Fate Therapeutics
Conditions:
Hematological Malignancy
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of the study is to assess long-term side effects from subjects who receive a Fate Therapeutics genetically modified NK cell product. Subjects who previously took part in a Fate Therapeutic...
Detailed Description
This is a non-therapeutic, multi-center, long-term follow-up (LTFU) study of subjects who received a Fate Therapeutics NK cell product that has been modified by lentivirus-mediated genetically enginee...
Eligibility Criteria
Inclusion
- Received engineered cellular immunotherapy in a Fate Therapeutics Interventional Study
Exclusion
- • Not Applicable
Key Trial Info
Start Date :
October 4 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 9 2020
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT04093622
Start Date
October 4 2019
End Date
April 9 2020
Last Update
August 29 2022
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Phoenix, Arizona, United States, 85054
2
UC San Diego
San Diego, California, United States, 92037
3
University of Minnesota Masonic Cancer Center
Minneapolis, Minnesota, United States, 55455
4
MD Anderson Cancer Center
Houston, Texas, United States, 77030